NASDAQ:LEGN

Legend Biotech Competitors

$28.45
-1.86 (-6.14 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$28.27
Now: $28.45
$30.30
50-Day Range
$23.55
MA: $27.03
$30.31
52-Week Range
$23.41
Now: $28.45
$43.24
Volume306,709 shs
Average Volume378,382 shs
Market Capitalization$3.76 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Legend Biotech (NASDAQ:LEGN) Vs. ELAN, BMRN, GRFS, TEVA, ZLAB, and BHC

Should you be buying LEGN stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Legend Biotech, including Elanco Animal Health (ELAN), BioMarin Pharmaceutical (BMRN), Grifols (GRFS), Teva Pharmaceutical Industries (TEVA), Zai Lab (ZLAB), and Bausch Health Companies (BHC).

Elanco Animal Health (NYSE:ELAN) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Earnings and Valuation

This table compares Elanco Animal Health and Legend Biotech's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Elanco Animal Health$3.07 billion4.58$67.90 million$1.0628.07
Legend Biotech$64.39 million58.33$-132,970,000.00N/AN/A

Elanco Animal Health has higher revenue and earnings than Legend Biotech.

Profitability

This table compares Elanco Animal Health and Legend Biotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Elanco Animal Health-8.45%3.43%2.04%
Legend Biotech-543.73%-205.60%-43.03%

Analyst Ratings

This is a summary of recent recommendations for Elanco Animal Health and Legend Biotech, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Elanco Animal Health23602.36
Legend Biotech00303.00

Elanco Animal Health currently has a consensus target price of $31.35, suggesting a potential upside of 5.38%. Legend Biotech has a consensus target price of $50.6667, suggesting a potential upside of 78.09%. Given Legend Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Legend Biotech is more favorable than Elanco Animal Health.

Institutional & Insider Ownership

86.8% of Elanco Animal Health shares are held by institutional investors. Comparatively, 18.9% of Legend Biotech shares are held by institutional investors. 0.1% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Elanco Animal Health beats Legend Biotech on 8 of the 11 factors compared between the two stocks.

BioMarin Pharmaceutical (NASDAQ:BMRN) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Earnings and Valuation

This table compares BioMarin Pharmaceutical and Legend Biotech's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioMarin Pharmaceutical$1.70 billion8.22$-23,850,000.00$0.071,101.00
Legend Biotech$64.39 million58.33$-132,970,000.00N/AN/A

BioMarin Pharmaceutical has higher revenue and earnings than Legend Biotech.

Profitability

This table compares BioMarin Pharmaceutical and Legend Biotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioMarin Pharmaceutical45.74%4.34%2.84%
Legend Biotech-543.73%-205.60%-43.03%

Analyst Ratings

This is a summary of recent recommendations for BioMarin Pharmaceutical and Legend Biotech, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioMarin Pharmaceutical081102.58
Legend Biotech00303.00

BioMarin Pharmaceutical currently has a consensus target price of $117.50, suggesting a potential upside of 52.46%. Legend Biotech has a consensus target price of $50.6667, suggesting a potential upside of 78.09%. Given Legend Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Legend Biotech is more favorable than BioMarin Pharmaceutical.

Institutional & Insider Ownership

97.7% of BioMarin Pharmaceutical shares are held by institutional investors. Comparatively, 18.9% of Legend Biotech shares are held by institutional investors. 2.2% of BioMarin Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

BioMarin Pharmaceutical beats Legend Biotech on 8 of the 11 factors compared between the two stocks.

Grifols (NASDAQ:GRFS) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, earnings and valuation.

Earnings & Valuation

This table compares Grifols and Legend Biotech's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Grifols$5.71 billion2.17$700.16 million$1.1715.38
Legend Biotech$64.39 million58.33$-132,970,000.00N/AN/A

Grifols has higher revenue and earnings than Legend Biotech.

Profitability

This table compares Grifols and Legend Biotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Grifols12.79%10.65%4.79%
Legend Biotech-543.73%-205.60%-43.03%

Analyst Recommendations

This is a summary of recent ratings for Grifols and Legend Biotech, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Grifols02502.71
Legend Biotech00303.00

Legend Biotech has a consensus target price of $50.6667, suggesting a potential upside of 78.09%. Given Legend Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Legend Biotech is more favorable than Grifols.

Institutional and Insider Ownership

15.2% of Grifols shares are held by institutional investors. Comparatively, 18.9% of Legend Biotech shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Grifols beats Legend Biotech on 6 of the 10 factors compared between the two stocks.

Teva Pharmaceutical Industries (NYSE:TEVA) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, earnings and valuation.

Earnings & Valuation

This table compares Teva Pharmaceutical Industries and Legend Biotech's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teva Pharmaceutical Industries$16.89 billion0.71$-998,000,000.00$2.314.78
Legend Biotech$64.39 million58.33$-132,970,000.00N/AN/A

Legend Biotech has lower revenue, but higher earnings than Teva Pharmaceutical Industries.

Profitability

This table compares Teva Pharmaceutical Industries and Legend Biotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Teva Pharmaceutical Industries-24.17%19.32%4.89%
Legend Biotech-543.73%-205.60%-43.03%

Analyst Recommendations

This is a summary of recent ratings for Teva Pharmaceutical Industries and Legend Biotech, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Teva Pharmaceutical Industries19402.21
Legend Biotech00303.00

Teva Pharmaceutical Industries presently has a consensus target price of $11.80, suggesting a potential upside of 6.88%. Legend Biotech has a consensus target price of $50.6667, suggesting a potential upside of 78.09%. Given Legend Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Legend Biotech is more favorable than Teva Pharmaceutical Industries.

Institutional and Insider Ownership

51.2% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 18.9% of Legend Biotech shares are held by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Teva Pharmaceutical Industries beats Legend Biotech on 7 of the 11 factors compared between the two stocks.

Zai Lab (NASDAQ:ZLAB) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, earnings and valuation.

Earnings & Valuation

This table compares Zai Lab and Legend Biotech's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zai Lab$12.98 million905.24$-195,070,000.00($3.03)-43.77
Legend Biotech$64.39 million58.33$-132,970,000.00N/AN/A

Legend Biotech has higher revenue and earnings than Zai Lab.

Profitability

This table compares Zai Lab and Legend Biotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zai LabN/AN/AN/A
Legend Biotech-543.73%-205.60%-43.03%

Analyst Recommendations

This is a summary of recent ratings for Zai Lab and Legend Biotech, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zai Lab00503.00
Legend Biotech00303.00

Zai Lab presently has a consensus target price of $159.00, suggesting a potential upside of 19.88%. Legend Biotech has a consensus target price of $50.6667, suggesting a potential upside of 78.09%. Given Legend Biotech's higher possible upside, analysts clearly believe Legend Biotech is more favorable than Zai Lab.

Institutional and Insider Ownership

81.3% of Zai Lab shares are held by institutional investors. Comparatively, 18.9% of Legend Biotech shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Zai Lab beats Legend Biotech on 6 of the 9 factors compared between the two stocks.

Bausch Health Companies (NYSE:BHC) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, earnings and valuation.

Earnings & Valuation

This table compares Bausch Health Companies and Legend Biotech's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bausch Health Companies$8.60 billion1.27$-1,788,000,000.00$4.436.95
Legend Biotech$64.39 million58.33$-132,970,000.00N/AN/A

Legend Biotech has lower revenue, but higher earnings than Bausch Health Companies.

Profitability

This table compares Bausch Health Companies and Legend Biotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bausch Health Companies-23.92%173.20%4.21%
Legend Biotech-543.73%-205.60%-43.03%

Analyst Recommendations

This is a summary of recent ratings for Bausch Health Companies and Legend Biotech, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bausch Health Companies14702.50
Legend Biotech00303.00

Bausch Health Companies presently has a consensus target price of $32.5833, suggesting a potential upside of 5.86%. Legend Biotech has a consensus target price of $50.6667, suggesting a potential upside of 78.09%. Given Legend Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Legend Biotech is more favorable than Bausch Health Companies.

Institutional and Insider Ownership

62.9% of Bausch Health Companies shares are held by institutional investors. Comparatively, 18.9% of Legend Biotech shares are held by institutional investors. 12.1% of Bausch Health Companies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Bausch Health Companies beats Legend Biotech on 7 of the 11 factors compared between the two stocks.


Legend Biotech Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Elanco Animal Health logo
ELAN
Elanco Animal Health
1.4$29.75-0.5%$14.07 billion$3.07 billion-52.19
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.9$77.07-1.5%$14.01 billion$1.70 billion17.64Insider Selling
News Coverage
Grifols logo
GRFS
Grifols
1.3$18.00-1.8%$12.38 billion$5.71 billion16.07
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.4$11.04-0.5%$12.06 billion$16.89 billion-3.00News Coverage
Zai Lab logo
ZLAB
Zai Lab
1.4$132.63-0.2%$11.75 billion$12.98 million-43.77Insider Selling
Bausch Health Companies logo
BHC
Bausch Health Companies
1.7$30.78-0.0%$10.95 billion$8.60 billion-5.65
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.3$63.92-1.8%$10.63 billion$2.32 billion52.83Analyst Upgrade
News Coverage
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$161.40-0.3%$9.09 billion$2.16 billion50.91Insider Selling
United Therapeutics logo
UTHR
United Therapeutics
1.5$203.36-1.3%$9.06 billion$1.45 billion19.24Analyst Report
Analyst Revision
News Coverage
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.6$34.66-4.1%$8.93 billionN/A0.00Analyst Downgrade
High Trading Volume
News Coverage
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$170.17-1.8%$8.62 billion$3.34 million-22.10Insider Selling
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0$54.49-6.7%$8.12 billion$40.56 million-15.98Gap Down
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.6$103.48-3.0%$6.93 billion$103.71 million-23.57News Coverage
Gap Down
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$217.93-0.0%$6.83 billion$311.33 million-126.70Insider Selling
News Coverage
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$125.61-3.1%$6.75 billion$14.98 million-15.30Gap Down
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$62.15-2.5%$6.45 billion$87.99 million-73.99News Coverage
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$44.79-4.3%$6.30 billion$150,000.00-21.13Gap Down
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$42.36-0.8%$5.97 billion$1.12 billion88.25
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$70.54-1.3%$5.60 billion$380.83 million-9.02
Allakos logo
ALLK
Allakos
1.7$105.00-2.9%$5.58 billionN/A-38.32Insider Selling
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$94.16-0.1%$5.46 billion$66.51 million17.37
Perrigo logo
PRGO
Perrigo
2.5$40.53-0.8%$5.41 billion$4.84 billion-675.39Analyst Report
News Coverage
Schrödinger logo
SDGR
Schrödinger
1.5$73.90-4.1%$5.17 billion$85.54 million0.00Insider Selling
Gap Down
Galapagos logo
GLPG
Galapagos
1.3$77.81-0.1%$5.10 billion$1.00 billion-11.79
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
1.8$56.51-0.5%$4.68 billionN/A0.00Analyst Report
News Coverage
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$76.61-0.7%$4.47 billion$6.87 million-7.40Analyst Report
Analyst Revision
News Coverage
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$69.39-2.2%$4.31 billionN/A-5.66Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.24-2.3%$4.26 billion$204.89 million-36.55News Coverage
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$77.35-1.6%$4.12 billion$1.11 billion24.87Analyst Report
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.5$66.29-0.3%$4.00 billion$806.43 million-9.39
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$78.95-3.9%$3.87 billionN/A-22.49Analyst Report
I-Mab logo
IMAB
I-Mab
1.4$51.65-2.3%$3.72 billion$4.31 million-1.79
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$52.77-0.3%$3.67 billion$117.91 million-10.70News Coverage
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$49.41-0.6%$3.44 billion$36.13 million-73.75Unusual Options Activity
News Coverage
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.63-3.3%$3.40 billion$114.62 million-7.51Analyst Report
Analyst Revision
Gap Down
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$47.60-1.4%$3.35 billion$306.98 million-6.81
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$41.56-0.0%$3.34 billionN/A-5.60
Insmed logo
INSM
Insmed
1.2$31.70-2.0%$3.27 billion$136.47 million-12.19Analyst Upgrade
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$20.39-1.4%$3.26 billion$339.08 million-11.85Analyst Downgrade
Analyst Revision
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$88.42-7.3%$3.20 billion$26.52 million-7.79Unusual Options Activity
Gap Down
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.6$116.91-0.9%$3.16 billionN/A-58.16News Coverage
Arvinas logo
ARVN
Arvinas
1.5$63.49-1.5%$3.10 billion$42.98 million-24.80Insider Selling
Alkermes logo
ALKS
Alkermes
1.2$19.02-0.2%$3.03 billion$1.17 billion-41.35Unusual Options Activity
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.0$68.25-0.4%$2.99 billion$421.03 million24.03Analyst Downgrade
Analyst Revision
Gap Down
MorphoSys logo
MOR
MorphoSys
0.3$22.36-0.8%$2.94 billion$80.43 million106.48Analyst Report
Organogenesis logo
ORGO
Organogenesis
1.0$22.84-4.9%$2.92 billion$260.98 million-380.67Gap Up
Viela Bio logo
VIE
Viela Bio
0.8$53.01-0.0%$2.91 billion$50 million-7.55
OPKO Health logo
OPK
OPKO Health
1.9$4.18-2.2%$2.80 billion$901.90 million-23.22
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.83-0.2%$2.79 billion$644.77 million-10.39Analyst Upgrade
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.68-1.0%$2.66 billion$306.49 million25.48Insider Selling
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.